about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaCombined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasNilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia.Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost?Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli.Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells.Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia.Curing chronic myeloid leukemia.Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.Treatment-free remission in patients with chronic myeloid leukemia.Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuationVascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells.Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale.Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses.Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure.
P50
Q26749324-81424552-5226-4481-B35B-EC1D9E6BD01AQ33187375-829F1960-4B44-49FE-AABF-27F5C087A1E1Q33379934-A346199A-D776-454E-8326-1E1950C8839FQ33393383-8B652812-4B80-4E3E-AC8F-2926440D07E5Q33396001-F5B83333-EF5E-4B9F-995B-7914BFE8AB5CQ33402841-2F3F83A8-0D5F-4111-BBBD-F795F259AED1Q33411250-6D3AEF33-B7D3-4CA6-808C-466DE5697599Q33439536-93B9E3CD-3C5C-4484-8C0A-E8615EF255DDQ33828570-7A6C7B84-717F-4E6D-B4C0-91E97B370C09Q33890580-FAEDBFFD-1BCE-4EDC-B66E-85C31C4D2E44Q34597819-403A8FD5-9131-49E1-B8DE-2C7283A6D35AQ34890400-607A6609-CA3F-4AD5-8B71-EE5122A73E27Q35834680-7A6B9576-5687-4AD3-BDE4-763060CB8548Q36376315-6FD82758-0FB9-4793-9551-A892B14CEDEAQ36442499-7A7FC9F1-AD6C-40EB-A088-ABF42D3ABBA7Q37391801-ED2335D8-B91F-4F01-BCB8-AA97BC780CCFQ37604767-87B80138-B0EA-4926-A9B6-2DB8E44E425AQ37988046-F398A61E-17FE-4A85-BBC6-3F5B58BF1346Q37992839-A39BFE37-70F6-46B3-9B53-3B0F59F37F40Q38376608-8549A462-E5E6-4F3A-9109-7B9CA0516D05Q38392679-0E7FDD92-C51F-4BAD-AE41-1AC7241F0E2BQ38568955-FD27845B-64EF-4C57-9768-7A6A18FC97D3Q39423384-63A69FF9-C440-4337-B726-035D5B9AFEFCQ40078173-B769209E-92F6-4D71-953E-131C5CA4F96AQ40188968-422D0B7F-8ECD-4F61-AA7F-548A854958C3Q40296130-4DF36B2C-D551-44A0-899F-86AE0EC93790Q40434005-1ACBF238-7D05-4C15-93DB-B637002CE0CBQ41610510-A1FF947F-F1C9-40D7-97D8-E072EC9201FFQ41668621-9359EC78-7D85-48B8-A032-55A8957D5925Q41980844-2AEC57F5-DB65-4EFF-A1CB-4C0E6F2195A5Q42380779-F93D5462-F942-40E7-86A5-F1DF69899D70Q42851077-77E1CC56-CECB-47C0-8496-4A9F2FCA9003Q43074099-3BCF4356-F8F3-409D-A367-2A5BBE8E8A7BQ43567134-75C8881D-5BC7-4364-832A-7DF478CE5E7EQ43867310-BDC23544-0B9F-480B-80DF-668531598401Q44493549-C6B13485-6C93-4713-856E-737F58FAA665Q44671240-028145BE-FA02-4D8D-A4CE-D26438F8E7D0Q44759324-40753852-2F8D-4B8F-A4C3-5241B6E3A03BQ45780787-DAD5D5EB-A250-4AB9-A57E-6ADA7D2C9C29Q45964946-59B0CAA1-F2C0-4CA3-9469-2B2842793CEA
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Delphine Rea
@ast
Delphine Rea
@en
Delphine Rea
@es
Delphine Rea
@nl
Delphine Rea
@sl
type
label
Delphine Rea
@ast
Delphine Rea
@en
Delphine Rea
@es
Delphine Rea
@nl
Delphine Rea
@sl
prefLabel
Delphine Rea
@ast
Delphine Rea
@en
Delphine Rea
@es
Delphine Rea
@nl
Delphine Rea
@sl
P106
P1153
35592307000
P21
P31
P496
0000-0001-5379-7461